Yale lifts a genetic brake on kidney protein in mice

In Yale's cell models and genetically engineered mice, a small stretch of genetic code acted like a brake on a kidney protein. When researchers disrupted that sequence, polycystin-1 production rose approximately twofold to fourfold. In mice predisposed to autosomal dominant polycystic kidney disease, or ADPKD, kidney cysts did not develop.

The protein matters because ADPKD mutations reduce the amount of functional polycystin-1 available to the kidneys. Fluid-filled cysts gradually enlarge and replace healthy tissue, driving a progressive loss of kidney function. ADPKD is the most common inherited cause of kidney failure, and many patients eventually need dialysis or a kidney transplant.

Whitney Besse, an assistant professor of medicine in nephrology at Yale School of Medicine, and Zhigui Li, an associate research scientist in her lab, focused on upstream open reading frames, or uORFs. These are short genetic sequences located before the main protein-coding section of a gene. The team's experiments suggest that active uORFs make cells less efficient at producing polycystin-1; blocking them releases that constraint.

The next step is not a human trial. Besse's team is testing antisense oligonucleotides, RNA-like genetic therapies that can block uORFs, in mice, while investigating which mutations could identify the patients most likely to benefit and how to reach the kidneys effectively. Yale Ventures has supported a patent as the researchers work toward a potential therapy.

So what changes for patients today? Nothing yet: the evidence comes from cells and mice. But the direction is concrete. Instead of trying to switch off a faulty disease gene, the approach seeks to increase production of the protein that is already in short supply—a strategy that could eventually add an option for families living with ADPKD if it proves safe and effective in further studies.